We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
In the latest trading session, Boston Scientific (BSX - Free Report) closed at $95.85, marking a -1.82% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.34%. Meanwhile, the Dow experienced a rise of 0.09%, and the technology-dominated Nasdaq saw an increase of 0.42%.
Heading into today, shares of the medical device manufacturer had lost 8.47% over the past month, lagging the Medical sector's gain of 1.97% and the S&P 500's gain of 3.54%.
The upcoming earnings release of Boston Scientific will be of great interest to investors. The company's earnings report is expected on October 22, 2025. It is anticipated that the company will report an EPS of $0.71, marking a 12.7% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $4.95 billion, indicating a 17.69% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $2.98 per share and revenue of $19.84 billion, which would represent changes of +18.73% and +18.46%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Boston Scientific. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.01% decrease. Boston Scientific presently features a Zacks Rank of #3 (Hold).
In terms of valuation, Boston Scientific is currently trading at a Forward P/E ratio of 32.81. For comparison, its industry has an average Forward P/E of 18.43, which means Boston Scientific is trading at a premium to the group.
One should further note that BSX currently holds a PEG ratio of 2.35. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Products was holding an average PEG ratio of 2.27 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 81, finds itself in the top 33% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
In the latest trading session, Boston Scientific (BSX - Free Report) closed at $95.85, marking a -1.82% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.34%. Meanwhile, the Dow experienced a rise of 0.09%, and the technology-dominated Nasdaq saw an increase of 0.42%.
Heading into today, shares of the medical device manufacturer had lost 8.47% over the past month, lagging the Medical sector's gain of 1.97% and the S&P 500's gain of 3.54%.
The upcoming earnings release of Boston Scientific will be of great interest to investors. The company's earnings report is expected on October 22, 2025. It is anticipated that the company will report an EPS of $0.71, marking a 12.7% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $4.95 billion, indicating a 17.69% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $2.98 per share and revenue of $19.84 billion, which would represent changes of +18.73% and +18.46%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Boston Scientific. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.01% decrease. Boston Scientific presently features a Zacks Rank of #3 (Hold).
In terms of valuation, Boston Scientific is currently trading at a Forward P/E ratio of 32.81. For comparison, its industry has an average Forward P/E of 18.43, which means Boston Scientific is trading at a premium to the group.
One should further note that BSX currently holds a PEG ratio of 2.35. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Products was holding an average PEG ratio of 2.27 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 81, finds itself in the top 33% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.